Lucia Varela-Otero

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

The impact of smoking and obesity on secukinumab effectiveness in psoriatic arthritis: real-world evidence from 1202 European patients.

The impact of smoking and obesity on secukinumab effectiveness in psoriatic arthritis: real-world evidence from 1202 European patients.

Journal: EULAR rheumatology open

Published: June 29, 2026

Impact of cardiometabolic comorbidities on clinical characteristics, prescription patterns and retention rate of first b/tsDMARD treatment in 5299 European real-world patients with psoriatic arthritis.

Impact of cardiometabolic comorbidities on clinical characteristics, prescription patterns and retention rate of first b/tsDMARD treatment in 5299 European real-world patients with psoriatic arthritis.

Journal: RMD open

Published: October 28, 2025

Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study): effect of regulatory warnings.

Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study): effect of regulatory warnings.

Journal: Seminars in arthritis and rheumatism

Published: October 02, 2025

Applying the hospital administrative data quality scoring tool in 15 countries.

Applying the hospital administrative data quality scoring tool in 15 countries.

Journal: Health information management : journal of the Health Information Management Association of Australia

Published: August 21, 2025

Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease-modifying antirheumatic drugs: results from the BIOBADASER III registry.

Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease-modifying antirheumatic drugs: results from the BIOBADASER III registry.

Journal: Rheumatology (Oxford, England)

Published: July 22, 2025

One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registry.

One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registry.

Journal: Reumatologia clinica

Published: December 24, 2024

Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries.

Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: November 07, 2024

Gender differences in clinical and prescribing characteristics of biologic and targeted synthetic drugs in naïve patients with rheumatoid arthritis: Data from BIOBADASER III registry.

Gender differences in clinical and prescribing characteristics of biologic and targeted synthetic drugs in naïve patients with rheumatoid arthritis: Data from BIOBADASER III registry.

Journal: Arthritis research & therapy

Published: October 14, 2024

Development of Data Quality Indicators for Improving Hospital International Classification of Diseases-Coded Health Data Quality Globally.

Development of Data Quality Indicators for Improving Hospital International Classification of Diseases-Coded Health Data Quality Globally.

Journal: Medical care

Published: July 10, 2024

Recording of non-musculoskeletal manifestations, comorbidities and safety outcomes in European spondyloarthritis registries: a survey.

Recording of non-musculoskeletal manifestations, comorbidities and safety outcomes in European spondyloarthritis registries: a survey.

Journal: Rheumatology advances in practice

Published: July 03, 2024

Long-Term Survival of Subcutaneous Biosimilar Tumor Necrosis Factor Inhibitors Compared to Originators: Results From a Multicenter Prospective Registry.

Long-Term Survival of Subcutaneous Biosimilar Tumor Necrosis Factor Inhibitors Compared to Originators: Results From a Multicenter Prospective Registry.

Journal: The Journal of rheumatology

Published: May 10, 2024

Sex differences in patient-reported outcome measures and the association with clinical factors in axial spondyloarthritis patients treated with tumour necrosis factor inhibitors.

Sex differences in patient-reported outcome measures and the association with clinical factors in axial spondyloarthritis patients treated with tumour necrosis factor inhibitors.

Journal: Rheumatology (Oxford, England)

Published: March 04, 2024

Showing 1-12 of 23

Last Updated: 09/26/2026